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Abstract: Clinical and preclinical research with modulators binding to the NMDA receptor GluN2B
N-terminal domain (NTD) aim for the treatment of various neurological diseases. However, the in-
terpretation of the results is hampered by the lack of a suitable NMDA PET tracer for assessing the
receptor occupancy of candidate drugs. We have developed [11C]Me-NB1 as a PET tracer for imaging
GluN1/GluN2B-containing NMDA receptors and used it to investigate in rats the dose-dependent re-
ceptor occupancy of eliprodil, a GluN2B NTD modulator. Methods: [11C]Me-NB1 was synthesized and
characterized by in vitro displacement binding experiments with rat brain membranes, in vitro autora-
diography, blocking and displacement experiments by PET and PET kinetic modeling with an arterial
input function. Receptor occupancy by eliprodil was studied in vivo by PET with [11C]Me-NB1. Re-
sults: [11C]Me-NB1 was synthesized at 290±90 GBq/µmol specific activity, 7.4±1.9 GBq total activity
at the end of synthesis and >99% radiochemical purity. [11C]Me-NB1 binding in rat brain was blocked
in vitro and in vivo by the NTD modulators Ro-25-6981 and eliprodil. In vivo, half maximal receptor
occupancy by eliprodil occurred at 1.5 ￿g/kg. At 1 mg/kg eliprodil, a dose with reported neuroprotective
effects, >99.5% binding sites were occupied. In vitro, [11C]Me‑NB1 binding was independent of sigma 1
receptor (Sigma1R) and the Sigma1R agonist (+)‑pentazocine did not compete for high affinity binding.
In vivo, 2.5 mg/kg (+)‑pentazocine abolished [11C]Me-NB1 specific binding, indicating an indirect effect
of Sigma1R on [11C]Me-NB1 binding. Conclusion: [11C]Me-NB1 is suitable for the in vivo imaging of
NMDA GluN1/GluN2B receptors and the assessment of the receptor occupancy by NTD modulators.
GluN1/GluN2B NMDA receptors are fully occupied at neuroprotective doses of eliprodil. Furthermore,
[11C]Me-NB1 enables imaging of GluN1/GluN2B NMDA receptor crosstalk.
DOI: https://doi.org/10.2967/jnumed.117.200451
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imaging  GluN1/GluN2B‐containing  NMDA  receptors  and  used  it  to  investigate  in  rats  the  dose‐
dependent  receptor  occupancy  of  eliprodil,  a  GluN2B  NTD  modulator.  Methods:  11C‐Me‐NB1  was 
synthesized and characterized by in vitro displacement binding experiments with rat brain membranes, 
in  vitro  autoradiography,  blocking  and  displacement  experiments  by  PET  and  PET  kinetic  modeling. 
Receptor  occupancy  by  eliprodil  was  studied  by  PET  with  11C‐Me‐NB1.  Results:  11C‐Me‐NB1  was 
synthesized at 290±90 GBq/µmol molar activity, 7.4±1.9 GBq total activity at the end of synthesis (n=17) 
and >99% radiochemical purity. 11C‐Me‐NB1 binding in rat brain was blocked in vitro and in vivo by the 
NTD modulators  Ro‐25‐6981  and  eliprodil.  Half maximal  receptor  occupancy  by  eliprodil  occurred  at 
1.5 μg/kg. At 1 mg/kg eliprodil, a dose with reported neuroprotective effects, >99.5% binding sites were 
occupied. In vitro, 11C‐Me‐NB1 binding was independent of sigma 1 receptor (Sigma1R) and the Sigma1R 
agonist  (+)‐pentazocine  did  not  compete  for  high  affinity  binding.  In  vivo,  2.5 mg/kg  (+)‐pentazocine 
abolished 11C‐Me‐NB1 specific binding, indicating an indirect effect of Sigma1R on 11C‐Me‐NB1 binding. 
Conclusion:  11C‐Me‐NB1  is  suitable  for  the  in vivo  imaging of NMDA GluN1/GluN2B receptors and  the 
assessment  of  the  receptor  occupancy  by  NTD modulators.  GluN1/GluN2B  NMDA  receptors  are  fully 









treatment  of  cerebral  ischemia,  Alzheimer’s,  Huntington’s  and  Parkinson’s  disease,  depression, 
neuropathic pain and schizophrenia (1). A functional NMDA receptor consists of four subunits out of the 
3 subfamilies GluN1, GluN2A‐D and GluN3A,B. Typically, two subunits are GluN1 while the other two are 
mainly  from  the  GluN2  subfamily  (1,2).  The  receptor  is  co‐activated  by  glutamate  and  glycine  or D‐










and  no  modulatory  effect  at  hGluN1/hGluN2A  receptors.  It  has  33‐  and  100‐fold  selectivity  for 
hGluN1/hGluN2B over human Sigma1R and sigma 2 receptors (Sigma2R), respectively (7). Applying 11C‐
Me‐NB1, we characterized the distribution pattern of NTD modulator binding sites in the rat brain and 
investigated  their dose‐dependent occupancy by eliprodil  (Ki=13 nM  for hGluN1/hGluN2B; Ki=132 and 
634 nM  rat  Sigma1R and  Sigma2R,  respectively)  (8).  Furthermore, we examined whether  11C‐Me‐NB1 
PET can be used to investigate receptor cross‐talk involving GluN1/GluN2B receptors. 
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in  n‐octanol/phosphate‐buffered  saline  pH  7.4.  Binding  affinities  were  determined  in  competition 









11C‐Me‐NB1  in  250  µL  saline  containing  ≤8%  ethanol.  Rats  were  sacrificed  by  decapitation  under 
isoflurane anesthesia 15 min after  tracer  injection. Tissues were dissected, weighed,  radioactivity was 
quantified and standardized uptake values (SUV, Supplemental Fig. 1) were calculated. 
PET experiments with an input function 
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tail  vein.  Data  were  acquired  for  60  min,  followed  by  a  CT.  Rats  were  euthanized  under  anesthesia 
immediately  after  the  scan.  Between  28  and  31 min  before  scan  start,  rats  were  injected 
intraperitoneally with either 25 mg/kg ketamine in water (25 mg/mL; 3 rats) or water alone (1 mL/kg; 4 
rats).  Two  (with  ketamine)  and  3  (baseline)  blood  curves  were  available  for  analysis,  as  the  arterio‐
venous  shunt  became  clogged  in  2  rats.  The  ratios  of  parent  tracer/total  radioactivity  in  plasma  and 
homogenized brain were determined  from additional  rats. The radioactivity  ratio plasma/whole blood 
was 1.11. 
PET experiments without an input function 
Twenty‐three Wistar  rats  (327‐409  g)  were  scanned  as  described  above,  without  an  arterio‐
venous  shunt.  Anaesthesia  was  induced  15‐35 min  before  tracer  injection.  Test  compounds  in  <1mL 














PET  data  were  reconstructed  as  described  in  Supplemental  Fig.  1.  Images  and  time‐activity 
curves  (TAC)  were  generated  with  PMOD  v3.7  (PMOD  Technologies,  Zurich,  Switzerland)  with 
predefined regions of interest, modified from the PMOD template (Supplemental Fig. 1). Scans with an 
input function were analyzed with Matlab (MathWorks, Natick, MA) by compartment modelling (14,17). 




(VS=K1/k2×k3/k4),  V  of  non‐displaceable  tracer  (VND=K1/k2)  and  the  V  ratio  VT/VND  (DVR)  and  binding 
potential  (BPND=k3/k4=DVR‐1) were  calculated  (17,18). VT was  in  addition  determined  from  the  Logan 
plot  (VT,Logan),  (17,19).  Blood  coincidence  start  time  and  background,  and  a  bi‐exponential  function 
describing  the  ratio parent/total  radioactivity  in  plasma were  fitted  together with  the  rate  constants. 
Results were confirmed with the PKIN module of PMOD v3.9. For the fits of the individual brain regions 
and  truncated  scan  durations,  only K1  to k4 were  fitted,  all  other  parameters were  used  as  fitted  for 
whole brain. 
For quantification without an  input  function, SUV was averaged  from 0  to 60 min  (SUV0‐60min). 
For the receptor occupancy study, SUV0‐60min were fitted with the function in Equation 1. 
SUV0‐60min=(SUV0‐60min,max – SUV0‐60min,min) × D50/(D50+d) + SUV0‐60min,min  Eq. 1 
SUV0‐60min,min  and SUV0‐60min,max are  the plateaux, d  is  the sum of  the eliprodil and  11C‐Me‐NB1/Me‐NB1 
doses, with the latter multiplied with a weighting factor f. The fitted parameters were D50, f, SUV0‐60min,min 
and  SUV0‐60min,max.  Receptor  occupancy  (d/(D50+d)) was  calculated  by  re‐arranging  Equation  1.  Specific 
binding in % was calculated as (SUV0‐60min,max‐SUV0‐60min,min)/SUV0‐60min,max*100%. 
use only. 




Mean values are  shown with  standard deviations  and  compared by a homoscedastic,  2‐tailed 
Student’s  t‐test  (without  correction  for  multiple  comparisons).  The  Akaike  information  criterion, 
corrected for finite sample size was calculated according to (20). 
use only. 
























for cortex, 2.8±0.8 for cerebellum and 2.7±0.7 for olfactory bulb  (n=8). Eliprodil  (2 mg/kg  i.v.) reduced 
11C‐Me‐NB1  accumulation  in  all  brain  regions.  The  relative  reduction was  highest  for midbrain,  brain 
use only. 
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stem,  cortex  and  striatum  (all  >40%  and  significant)  and  lowest  and  not  significant  for  hippocampus 
(31.9%) and cerebellum (34.5%). In peripheral tissues, accumulation was highest in adrenal glands (SUV 










two‐tissue  compartment model and  the  respective Logan plots  are  shown  in Fig.  3  (whole brain) and 
Supplemental  Figs.  5  and  6  (regions).  Parametric  maps  for  VT  for  the  scan  in  Fig.  2A  are  shown  in 
Supplemental  Fig.  7.  VT,fit  and  VT,Logan,  of  12  brain  regions  each  of  the  5  scans  are  depicted  in 
Supplemental  Fig.  8.  Supplemental  Fig.  9  shows  the  fit  of  the  data  in  Fig.  3  with  a  one‐tissue 
compartment model  and  the  residuals  for both models.  The Akaike  information  criterion  favored  the 
two‐tissue compartment model. For all scans, VT,fit of whole brain remained within ±5% when the scan 
end  time  for  data  analysis  was  reduced  to  any  time  between  13  and  60  min  (Fig.  3D).  Ignoring 
radiometabolite distribution to the brain resulted in similar fit parameters. Supplemental Tables 2 to 4 












ketamine  challenge were  in  agreement with VT,fit  values  (Supplemental  Fig.  10).  The  sub‐therapeutic 
dose of ketamine was administered to  investigate whether changes  in glutamate  levels affect  11C‐Me‐
NB1  accumulation  (24).  Our  results  (VT  and  SUV0‐60min)  excluded  a  major  influence  of  ketamine  on 










(+)‐pentazocine  and  haloperidol  to  modulate  Sigma1R  and  dopamine  receptors,  respectively.  Both 
(+)‐pentazocine  and haloperidol  showed only weak  competition with  3H‐ifenprodil  in  the  competition 
binding assays. (+)‐Pentazocine brain concentrations were aimed at 350‐2000 nM (28) and the dose of 
haloperidol corresponded to 10‐fold the D50 in a D2/D3 receptor occupancy study with 11C‐raclopride in 
rats  (16).  At  these  concentrations,  Sigma1Rs  and  D2/D3  receptors,  respectively,  should  be  occupied, 
use only. 





To  definitely  exclude  both  a  direct  competition  between  11C‐Me‐NB1  and  (+)‐pentazocine 
binding and high affinity binding of 11C‐Me‐NB1 to Sigma1R, we performed in vitro autoradiography with 
brain slices from Sigma1R knockout mice (Fig. 5E,F, Supplemental Fig. 14). 11C‐Me‐NB1 binding was not 
different between  slices  from wild  type and  Sigma1R knock out mice,  excluding  significant binding of 
11C‐Me‐NB1 to Sigma1R. (+)‐Pentazocine (1 µM) reduced the binding for both genotypes by < 10% (p < 
0.05) while  the  same  concentration  of  eliprodil  reduced  the  binding  for  both  genotypes  by  40%  (p  < 
0.01),  similar  as  in  the  ex  vivo  biodistribution  experiment  and  receptor  occupancy  study. 
Autoradiography  at  3  different  11C‐Me‐NB1  concentrations  revealed  high‐affinity  binding  in  all  brain 
regions  of  rat,  mouse  and  Sigma1R  knockout  mouse,  including  the  GluN2B‐free  cerebellum,  in 
agreement with the PET results. 
use only. 




Till  to  date,  no  clinically  validated  PET  radioligand  exists  for  the  imaging  of NMDA  receptors. 
Reasons for failure include lack of in vivo specificity and selectivity, low affinity, poor metabolic stability 
and poor distribution to the brain (29‐34). Aiming to overcome the shortcomings of previously reported 




11C‐Me‐NB1  binding  was  competed  by  low  doses  of  eliprodil  in  all  brain  regions,  including 
midbrain,  pons  and  cerebellum  with  low  GluN2B  levels  (35‐38).  Off‐target  binding  to  Sigma1R  was 
excluded  in  vitro.  The  GluN2B‐poor  regions  contain  significant  levels  of  GluN2D  or  GluN2C  (36). 
11C‐Me‐NB1  and  eliprodil  may  bind  to  these  or  alternative  GluN  receptor  subtypes  in  addition  to 
GluN1/GluN2B receptors. The high specific binding of 11C‐Me‐NB1 in adrenal glands, a tissue containing 
GluN1, GluN2C and GluN2D but not GluN2A or GluN2B (39) supports this hypothesis. 
In  preclinical  studies,  eliprodil  had  neuroprotective  effects  at  1  mg/kg  (4,40,41).  This 
corresponds  to  full  (99.5%)  receptor  occupancy  in  our  study.  As  discussed  by  Carter  et  al.  (4), 
antidepressant and anticonvulsive effects observed at even higher doses may have resulted from lower‐
affinity binding to alternative targets. 
The  Sigma1R  agonist  (+)‐pentazocine  abolished  11C‐Me‐NB1  specific  binding  in  the  rat  brain 
despite  the  lack  of  direct  competition  in  vitro.  (+)‐Pentazocine  stabilizes  the  Sigma1R  in  its 
dimeric/monomeric form(s), which interacts with other proteins (23). Besides indirect effects on NMDA 
receptors, e.g.,  phosphorylation,  a direct  interaction between Sigma1R and  the N‐terminal domain of 
GluN1  that  is  involved  in  the  interface  with  the  GluN2B  NTD  was  recently  demonstrated  (42).  This 
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interaction  may  directly  hamper  11C‐Me‐NB1  binding.  Alternatively,  direct  and/or  indirect  NMDA 
receptor modulation could bring the receptor to a conformation with reduced binding affinity for NTD 
ligands.  Finally,  altered  receptor  trafficking  and  cell‐surface  density  could  affect  11C‐Me‐NB1 
accumulation. 
Several  mechanisms  could  result  in  the  elimination  of  11C‐Me‐NB1  specific  binding  observed 
with haloperidol. Activation of dopamine receptors modulates NMDA receptor‐mediated Ca2+ currents 
and  treatment  of  rats  with  1  mg/kg  haloperidol  altered  the  phosphorylation  pattern  of  GluN1  and 
GluN2B  (6,26,43,44).  Haloperidol  furthermore  modulates  sigma  receptors  (7,45). We  did  not  further 
investigate  on  the  molecular  mechanisms.  However,  our  data  suggest  that  11C‐Me‐NB1  PET  could 
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Cb,  cerebellum. B) Brain  region TACs of a baseline  scan  (67 MBq; 2.1 nmol/kg; 394 g). C)  TACs under 
baseline conditions (, as in B), or with 1 mg/kg eliprodil i.v. 1 min before 11C‐Me‐NB1 (, blockade, 35 








FIGURE  3.  11C‐Me‐NB1 kinetic evaluation  in  rat whole brain. Representative  baseline  scan  (31.8 MBq; 
0.44 nmol/kg; 321 g). A) Whole brain TAC () and input functions (IF) as indicated. Black lines, fit results 
as indicated. 100 kBq/cm3 corresponds to ~ 0.4 nM 11C‐Me‐NB1. VT,fit=12.6 mL/cm3. B) Experimental and 
fit  ratios  of  parent  tracer/total  radioactivity  in  plasma  and  brain,  as  indicated.  Residuals  from  the 
experimental TAC and ratios parent/total radioactivity were minimized simultaneously during the fitting 























within  the  first  few minutes may be affected by drug‐induced changes  in cerebral blood  flow  (46,47), 
and increased plasma levels under blocking conditions (Fig. 3). B) 11C‐Me‐NB1 autoradiograms of brain 
slices  from  Sigma1R  knockout  and  wild  type  mice  as  indicated.  Incubation  with  4.0  nM  11C‐Me‐NB1 
alone  (baseline)  or  together  with  (+)‐pentazocine  or  eliprodil.  C) Quantitative  analysis  of  the 
autoradiograms in B. No significant difference between wild type and Sigma1R knockout mice for all 3 
conditions (p > 0.05). (+)‐Pentazocine (1 μM) reduced 11C‐Me‐NB1 binding in wildtype and Sigma1R ko 
mice  by  <  10%.  The  reduction  by  an  equal  concentration  of  eliprodil  was  40  and  42  %,  respectively 
(horizontal broken line, p < 0.05; solid lines, p < 0.01). a.u., arbitrary units. 
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Supplemental Figure 1. 11C-Me-NB1 PET images of rat brain, averaged from 3 individual scans, 0 to 60 
min after tracer injection. PET data were reconstructed with 2D Fourier rebinning/ordered-subsets 
expectation maximization algorithms (FORE/OSEM), 2 iterations, 16 subsets, into time frames 
between 20 and 180 s for kinetic modelling with an input function or between 120 and 300 s for scans 
without an input function. PET data were corrected for singles and randoms but not for attenuation. 
The brain region template used for the quantitative analysis is superimposed (PMOD). The volumes 
(mm3) of the individual regions of interest were pons, 45; striatum, 87; hypothalamus, 37; olfactory, 
28; superior colliculus, 14; midbrain, 23; cerebellum grey matter, 150; cerebellum white matter, 47; 
inferior colliculus, 11; thalamus, 61; cortex, 576; hippocampus, 70; whole brain, 1831; prefrontal 
cortex, 132. The standardized uptake values (SUV) were calculated as Bq per g tissue divided by 
injected Bq per g body weight. The SUV corresponds to % injected dose per g tissue multiplied with 
body weight (g) and divided by 100 %. Specific binding in % in the ex vivo biodistribution experiments 
were calculated as (SUV(baseline)-SUV(blockade))/SUV(baseline)*100. 
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Supplemental Figure 2. Characterization of 11C-Me-NB1 binding to rat brain tissue by in vitro 
autoradiography. Baseline and blocking conditions as indicated. Results from two independent 
experiments as indicated by the frames. Cb, cerebellum, for orientation. Intensity bar with maximal 
(max) and minimal (min) unmodified phosphorimager signal intensity (a.u.). Horizontal rat brain slices 
(20 µm) of adult male Wistar rats were incubated for 30 min at room temperature with 11C-Me-NB1 
alone or in combination with the indicated compounds, in HEPES buffer (30 mM HEPES, 110 mM NaCl, 
5 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, pH 7.4) containing 0.1 % bovine serum albumin (HEPES/BSA). 
After incubation, the slices were washed with HEPES/BSA (8 min), HEPES buffer (2×3 min) and water 
(2×5 s). The dried slices were exposed for 20 min to a phosphorimager plate and read in a phosphor-
imager BAS5000 (Fuji, Tokyo, Japan; software AIDA v4.5). Radioactivity accumulation was quantified 
with the software PMOD v3.7 (PMOD Technologies, Zurich, Switzerland). Note that the bivalent 
cations in the HEPES buffer could affect 11C-Me-NB1 binding (1). 
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Supplemental Figure 3. Distribution of 11C-Me-NB1 in rat tissues determined by dissection 15 min 
after 11C-Me-NB1 i.v. injection under baseline and blocking conditions, as indicated. Numbers show 
the percent specific binding. * indicates significant reduction (increase in the case of blood) by eliprodil 
(p < 0.05). # indicates significantly higher SUV than cerebellum under baseline conditions (p < 0.01, 
paired t-test, not corrected for multiple comparisons). A) Brain regions. B) All tissues, including whole 
brain (calculated from the SUV and tissue weights in A). 
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Supplemental Figure 4. Brain region TACs of 11C-Me-NB1 under baseline, blocking and displacement 
conditions. Same scans and conditions as shown in Fig. 2. , Baseline; , blockade with 1 mg/kg 
eliprodil (1 min before tracer injection); , displacement with 1 mg/kg eliprodil (20 min after tracer 










Supplemental Figure 5. 11C-Me-NB1 TACs and kinetic modeling for individual brain regions of the scan 
shown in Fig. 3. A) Striatum, B) hippocampus, C) pons, D) cerebellum grey matter. , experimental 
data; lines, dark grey, input function; light grey, input function of radiometabolite; black solid, fit TAC; 
pink dotted, tracer simulated in 2nd tissue compartment (specific binding); blue dotted, tracer 
simulated in 1st tissue compartment (non-displaceable); green, radiometabolite simulated in brain. 
The respective VT,fit (mL/cm3) are shown in the panels. Ratio parent/total radioactivity in plasma and 
brain: in a pilot experiment, a rat (339 g) was injected into a lateral tail vein 81.8 MBq 11C-Me-NB1 
under isoflurane anesthesia and sacrificed 5 min later by decapitation under anesthesia. The blood 
was collected and plasma was separated by centrifugation (5000 × g, 5 min, 4°C). The brain was 
homogenized in an equivalent volume of ice cold PBS for 1-2 min. The proteins in both samples were 
precipitated with equivalent volumes of ice cold acetonitrile and centrifugation as above. The analysis 
of the filtered supernatants by TLC (silica gel, MERCK KGaA; mobile phase, methanol) and the 
phosphorimager revealed a single, polar radiometabolite beside the parent tracer. To determine the 
ratio of parent tracer to total radioactivity in plasma and brain over time, 6 rats (227-421 g) were 
injected into a lateral tail vein with 28-37 MBq 11C-Me-NB1 and blood samples were drawn from the 
opposite vein at the indicated time points. The rats were sacrificed at 15, 30 and 60 min, respectively, 
and brains and blood were collected. Blood and brain samples were processed as above. The 
unfiltered supernatants after acetonitrile addition were diluted with 3 volumes of water. The solution 
was passed through a Sep-Pak C18 Light cartridge (Waters, Milford, MA) and washed with 1 mL water. 
The combined aqueous phase contained the polar radiometabolite. The parent compound was eluted 
with 1 mL ethanol. The separation was confirmed by TLC. The radioactivity in both aqueous and 
ethanol eluents was quantified in the gamma counter and the ratio parent to total radioactivity was 
calculated as the radioactivity in the ethanol phase divided by the sum of the radioactivity in both 
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phases. The ratio of plasma to whole blood radioactivity was determined from plasma and whole 
blood in the gamma counter, it was 1.11. Kinetic modeling: Scans with an input function were analyzed 
based on a two-tissue compartment model (2) with a home-written MATLAB script (MathWorks, 
Natick, MA). PET TACs and not-decay corrected blood coincidences were loaded. The start time of the 
blood coincidences curve and the background coincidences were estimated as the time point of the 
first significant increase in the data and the average counts before this time point, respectively. Both 
values were refined during the fitting procedure. The background- and start time-corrected 
coincidences were decay-corrected and multiplied with the experimentally determined calibration 
factor between the PET scanner and the coincidence counter and the plasma/blood radioactivity ratio 
of 1.11. They were further multiplied with a bi-exponential function (refined during the fitting 
procedure) to correct for the experimentally determined ratio parent/total radioactivity in plasma and 
the radiometabolite input function was revealed as the difference between the total and parent 
coincidences. These adapted input functions were convoluted with the weighting function for a two-
tissue compartment model for the parent tracer, defined by K1, k2, k3 and k4, and a one-tissue 
compartment model for the radiometabolite, defined by K1M and k2M (2). The squared residuals 
between the experimental data and the fit functions for the brain TAC (consisting of parent tracer, 
radiometabolite and blood radioactivity, assuming a partial volume of 5 % blood in the brain), as well 
as fit functions for the parent/total radioactivity in plasma and brain were minimized with the function 
fmincon and a multistart procedure with 64 runs. For whole brain, the difference between VT,fit and 
VT,Logan, determined from the Logan plot (3), were furthermore minimized to allow to accurately define 
the starting time and background coincidences of the blood coincidence curve. In addition, the 4 
parameters defining the ratio parent/total radioactivity in plasma were fit. In summary, the following 
parameters were fit simultaneously: K1, k2, k3, k4, input function start time, blood coincidence 
background, A, B, a and b of the function parent/total radioactivity in plasma = A×exp(-a×t)+B×exp(-
b×t)+(1-A-B), furthermore K1M and k2M. The parameters were fit by minimizing the differences 
between the fit and experimental brain TAC, the fit and experimental plasma and brain ratios parent 
tracer/total radioactivity and the VT,fit and VT,Logan. The resulting start time and background 
coincidences of the blood coincidence curve and the bi-exponential function defining the parent/total 
radioactivity ratio in plasma were then fixed to analyze the stability of K1 to k4 and the composite 
parameters for whole brain at truncated scan durations and for the individual brain regions at full scan 
time, in 8 runs each (multistart with fmincon). For comparison, K1M was fixed at 0, ignoring 
radiometabolite distribution to the brain. 
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Supplemental Figure 6. Logan plots for individual brain regions of the scan shown in Figure 3 and 
Supplemental Figure 5. A) Striatum, B) hippocampus, C) pons, D) cerebellum grey matter. Symbols 




Supplemental Figure 7. Parametric maps for VT (mL/cm3) for the scan shown in Fig. 2A. The maps were 
generated with PMOD v3.8 based on the input function (see above) and the image data. Vertical (left), 
sagittal (middle), horizontal (right) planes at  1.7 mm (left-right),  3.8 mm (dorsal-ventral),  0.4 mm 
(anterior-posterior) from Bregma (as in Fig. 2A). 
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Supplemental Figure 8. Comparison of VT,Logan and SUV0-60min with VT,fit. A) VT,Logan vs VT,fit of 5 scans and 
12 brain regions each. The correlation was VT,Logan = 1.04 × VT,fit – 0.03 mL/cm3 (r2 = 0.99). B) SUV0-60min 
vs VT,fit (same scans and regions as in A). The correlation was SUV0-60min = (0.209 cm3/mL) × VT,fit + 0.123; 
r2 = 0.913. 
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Supplemental Figure 9. The experimental brain TAC shown in Fig. 3 fit to one-tissue compartment 
models for both the parent tracer and the radiometabolite. A) Fit brain TAC. B) Simultaneously fit 
ratios parent tracer to total radioactivity in brain and plasma. C) Residuals for the brain TAC fit with a 
one-tissue compartment model each for parent tracer and radiometabolite. The corrected Akaike 
information criterion was 317.9. D) Residuals for the brain TAC fit with a two-tissue compartment 
model for the parent tracer and a one-tissue compartment model for the radiometabolite (residuals 
from fit shown in Fig. 3A), The Akaike information criterion was 266.1. Deviations from the 
experimental parent/total radioactivity ratios in plasma and brain were not included in the 
calculations of the Akaike information criterion. The model with the lower Akaike information criterion 









Supplemental Figure 10. Quantitative PET with and without an input function and influence of 
ketamine on 11C-Me-NB1 PET. VT,fit values (mL/cm3) from kinetic modeling and adjusted SUV0-60min as 
(SUV0-60min-0.123)/(0.209 cm3/mL), according to Supplemental Figure 8B. Scans without a meaningful 
input function were included for the adjusted SUV0-60min. Mean values with standard deviations (for n 
≥ 3), n as indicated. To study the influence of ketamine and glutamate in vivo, 3 of the 7 rats with 
input-function recording were administered intraperitoneally 25 mg/kg ketamine 30 min before tracer 
injection. The VT,fit values of the 2 ketamine-treated rats with complete input function were within the 
standard deviations of the respective values from the baseline scans or close to this range 
(Supplemental Tables 3 and 4) and no significant difference was detected between the respective 
SUV0-60min values. This excludes a major influence of the ketamine challenge on 11C-Me-NB1 
accumulation in rat brain under isoflurane anesthesia. VT,fit and adjusted SUV of all brain regions 
except olfactory bulb were significantly higher than the respective parameter of cerebellum grey 








Supplemental Figure 11. Receptor occupancy by eliprodil as determined by PET with 11C-Me-NB1 in 
individual brain regions as indicated. The regions and fit parameters are indicated in the panels. 
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Supplemental Figure 12. Weak or absent correlation between D50 and fitted non-displaceable tracer 
accumulation (SUV0-60min,min). SUV0-60min,max and SUV0-60min,min are the fitted maximal and minimal 
SUV0-60min of the receptor occupancy data of the various brain regions (Fig. 4 and Supplemental Fig. 
11). A) D50 vs SUV0-60min,min. B) D50 vs SUV0-60min,max. C) D50 vs SUV0-60min of specifically bound tracer. D) 
D50 vs the relative SUV0-60min,min. Linear regression analysis results are shown in the panels. 
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Supplemental Figure 13. Receptor occupancy estimated from the Lassen plot. A) Lassen plot according 
to Cunningham et al. (4). SUV0-60min,baseline was averaged from the two baseline scans with the lowest 
11C-Me-NB1 dose in nmol/kg, i.e., 0.5 and 1.3 nmol/kg (x-axis). The differences between the averaged 
regional baseline SUV0-60min values and the regional SUV0-60min values after eliprodil administration are 
plotted on the y-axis (increasing eliprodil dose from blue to red color). Under ideal conditions, the 
slope of the Lassen plot (symbols, linear regression of the data points at a particular dose, lines) equals 
the receptor occupancy as a fraction of 1 and the intercept with the x-axis equals the SUV0-60min in the 
absence of specific binding (4). B) , Slopes of the Lassen plot in A. Solid line, fit with a saturation 
function, the minimum was fixed at 0 and receptor occupancy by the tracer was neglected. Fitted D50 
(eliprodil dose at 50 % of fitted maximal occupancy) was 8.5 nmol/kg. Note that the Lassen plot 
assumes equal D50 and SUV0-60min,min for all brain regions and neglects occupancy by the tracer itself. 
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Supplemental Figure 14. In vitro autoradiography with brain slices from wt rats, wt mice and Sigma1R 
ko mice at 5.5 nM, 2.1 nM and 0.55 nM 11C-Me-NB1 as indicated (A) and with 10 µM eliprodil for 
blocking (B). C) Bound radioactivity was quantified with PMOD v3.8 by region-of-interest analysis for 
cerebrum (mice), frontal cortex (rat) and cerebellum. The background-corrected radioactivity was 
averaged for the two brain slices per slide. Black circles, total bound radioactivity (as in A, background-
corrected). Blue triangles, unspecific binding (as in B, background-corrected). Red squares, specifically 
bound tracer (difference between A and B). Note that specific binding is saturated already at the 
lowest investigated 11C-Me-NB1 concentration of 0.55 nM, in agreement with the high affinity 
observed in vivo (Fig. 2A and 4A). Note in addition the high specific binding in cerebellum of wt rat 
and mouse and of Sigma1R ko mouse, indicating off-target binding but excluding binding to Sigma1R. 
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Supplemental Table 1 Binding affinities determined with rat brain membranes a) 
Compound Tritiated compound Temperature 
(°C) 
IC50 (nM) b) Ki (nM) c) n d) 
Ro-25-6981 [3H]ifenprodil 20 44.7 ± 11.0 e) 42.3 ± 12.0 3 
  (+)-[3H]pentazocine 20 23.1 15.4 1 
Haloperidol [3H]ifenprodil 20 ~ 8000  1 
  37 ~ 6000  1 
  (+)-[3H]pentazocine 20 753 482 1 
  37 f) 38.0 31.9 1 
Eliprodil [3H]ifenprodil 20 51.4 ± 33.9, 
17-85 
48.5 ± 32.0, 
16-80 
3 
  (+)-[3H]pentazocine 37 335-1281 229-875 3 
Me-NB1 [3H]ifenprodil 20 42.4 ± 2.9 40.2 ± 2.8 4 
  (+)-[3H]pentazocine 37 > 4000  3 
a) Binding affinities were determined in a competition binding assay with rat brain membranes as 
described elsewhere (5-7) with 1 to 5 nM 3H-ifenprodil or (+)-3H-pentazocine  (both PerkinElmer, 
Schwerzenbach, Switzerland). Ifenprodil binds with a Kd of 37 nM to the rat GluN1/GluN2B NTD 
binding site (8)) while (+)-pentazocine binds with a Kd 7 nM to rat Sigma1R (9). Sample volumes were 
200 µL containing 0.1 mg (for assays with 3H-ifenprodil) or 0.2 mg (assays with (+)-3H-pentazocine) 
total protein in HEPES buffer (30 mM Na-HEPES, 110 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2 
at pH 7.4). Test compounds were added at various concentrations in triplicates and samples were 
incubated for 1 to 1.5 h at the indicated temperature or 2 to 2.5 h in the case of (+)-3H-pentazocine at 
37°C and filtered at 4°C as described elsewhere (5). The Ki values were calculated with the Cheng-
Prusoff equation from the IC50 values determined in the binding assay and Kd of the tritiated 
compounds for the respective rat receptors, as indicated. b) Average ± standard deviation and/or range 
in case of 3 or more independent experiments, or results of individual experiments; c) Calculated with 
the Cheng-Prusoff equation and ifenprodil Kd =37 nM to rat brain NTD binding site (8) and 
(+)-pentazocine Kd=7 nM to rat Sigma1R (9), respectively; d) number of independent experiments with 
triplicates for each test concentration; e) similar results at 4°C (n=2) and 37°C (n=2); the mean Ki 
including all temperatures was 49.8 ± 19.7 nM. f) Inverse Sigma1R agonists such as haloperidol induce 
the formation of Sigma1R tetra- and oligomers, the suggested resting states of Sigma1R (6). The 
reduced form of haloperidol, formed by metabolism, irreversibly inhibits the receptor, in addition (10). 
Both would explain the temperature-dependent competition with (+)-3H-pentazocine. Note that the 
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Supplemental Table 2. Details of the PET scans with input function recording 
Scan ID Treat-
ment a) 




1 V 320.6 31.83 0.44 
3 V 352.8 36.47 0.59 
5 V 319.1 51.66 0.78 
7 V 341.1 33.68 0.47 
Average ± SD V 333.4 ± 16.4 38.41 ± 9.0 0.57 ± 0.15 
2 K 328.4 33.16 0.69 
4 K 310.7 40.69 0.54 
6 K 341.4 38.5 0.46 
Average ± SD K 326.8 ± 15.4 37.5 ± 3.9 0.56 ± 0.12 
Average ± SD V,K 328.9 ± 17.5 39.8 ± 7.4 0.56 ± 0.14 
a) V, vehicle; K, ketamine (25 mg/kg intraperitoneally, 30 min before tracer). 
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1 V 2 12.57 12.54 2.67 9.14 3.43 2.94 0.19 266.1
  1 14.44  - - - 2.94 0.33 317.9
3 V 2 12.07 12.22 3.46 9.36 2.71 2.58 0.18 236.9
  1 11.87  - - - 2.58 0.14 332.7
5 V 2 10.71 10.68 3.19 8.15 2.56 2.41 0.17 250.4
  1 12.36  - - - 2.41 0.47 332.7
7 c) V 2 - - - - 2.92  
  1   - - 2.92  
Average 
± SD d) 
















V 1 12.89 
± 1.37 
 - - - 2.72 
± 0.26 
0.31 ± 0.16 327.7 
± 8.5 
2 c) K 2   - - - 2.71  
  1   - - - 2.71  
4 K 2 12.34 12.45 5.04 10.30 2.04 2.62 0.05 244.8
  1 16.44  - - - 2.62 0.38 341.9
6 K 2 11.49 11.59 4.50 9.40 2.09 2.42 0.15 225.3
  1 14.26  - - - 2.42 0.48 379.3
Average 
± SD 


























V,K 1 13.87 
± 1.83 
 - - - 2.59 
± 0.21 


















a) V, vehicle; K, ketamine (25 mg/kg intraperitoneally, 30 min before tracer). b) 1, One-tissue 
compartment model; 2, two-tissue compartment model for parent tracer. One-tissue compartment 
model for radiometabolite in both cases. c) No fit data available (see Methods). d) SD, standard 
deviations shown for n ≥ 3. e) Corrected Akaike information criterion (Methods); residues are from 
brain TACs, residues of parent to total radioactivity in brain and plasma were not taken into account. 
f) Distribution of the radiometabolite to the brain ignored.  
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Supplemental Table 4. Fit K1, k2, k3 and k4 of the individual scans of Supplemental Tables 2 and 3. 






k2 (1/min) k3 (1/min) k4 (1/min) 
1 V 2 2.15 0.63 0.64 0.24 
  1 1.70 0.12 - - 
3 V 2 2.42 0.89 0.63 0.18 
  1 1.55 0.13 - - 
5 V 2 2.64 1.03 0.75 0.24 
  1 1.71 0.14 - - 
7 c) V 2 - - - - 
  1 - - - - 
Average ± SD d) V 2 2.40 ± 0.25 0.85 ± 0.21 0.67 ± 0.07 0.22 ± 0.03 
Average ± SD V 1 1.66 ± 0.09 0.13 ± 0.01 - - 
2 c) K 2 - - - - 
  1 - - - - 
4 K 2 2.86 1.40 0.80 0.16 
  1 1.64 0.10 - - 
6 K 2 4.38 2.09 0.83 0.19 
  1 1.91 0.13 - - 
Average ± SD K 2 3.62 1.75 0.81 0.17 
Average ± SD K 1 1.77 0.12 - - 
Average ± SD V,K 2 2.89 ± 0.87 1.21 ± 0.57 0.73 ± 0.09 0.20 ± 0.04 
Average ± SD V,K 1 1.70 ± 0.13 0.12 ± 0.02 - - 
Average ± SD V,K 2 e) 2.91 ± 0.87 1.21 ± 0.56 0.74 ± 0.09 0.20 ± 0.04 
a) V, vehicle; K, ketamine (25 mg/kg intraperitoneally, 30 min before tracer). b) 1, One-tissue 
compartment model; 2, two-tissue compartment model for parent tracer. One-tissue compartment 
model for radiometabolite in both cases. c) No fit data available (see Methods). d) SD, standard 
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